High Fives All Around as Merck Takes Down Cubist
Research - Merck is buying Cubist for $102/share, valuing the antibiotics company at $9.5B including its cash. After the close on Monday, the U.S. District Court in Delaware … Continue Reading
PremiumAuthor Archives: Jake King
Puma Biotech’s Delay Increases Headline Risk in 2016
Insights - Puma Biotech (PBYI) on Tuesday evening announced a significant, unexpected delay in its timeline for filing a New Drug Application with the FDA for lead … Continue Reading
Read now
Small Drug Companies Get Love on Avanir Buyout
Insights - Japanese drugmaker Otsuka Pharmaceutical Co. is buying US-based Avanir Pharmaceuticals (AVNR) for $3.5 billion, or $17/share, in a deal announced Tuesday morning. Despite a tremendous run … Continue Reading
Read now
A Short-term Chart Trade and Options Idea for this Upcoming Data Release
Research - This company has a data release coming imminently. We've outlined one equity, and one options strategy for the event.
Premium
Trim this Position for an 18% Gain
Research - This thesis played out beautifully, and it's time to take some profit - 18% in just two weeks.
Premium
In Typical Biotech Fashion, Celldex Rips 40% in a Week’s Time
Insights - Celldex Therapeutics (CLDX) has climbed 100% from all-time lows this summer – 40% in the last week – on encouraging and arguably groundbreaking results from a phase II … Continue Reading
Read nowTake Advantage of this Trading Channel Before Year-End
Research - In the relative near-term, XOMA Corporation (XOMA) is guiding to complete and release results from EYEGUARD-B, a phase III study of the company’s lead drug candidate gevokizumab … Continue Reading
Premium